

SYK Antibody (C-term)
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP7720b**Specification**

SYK Antibody (C-term) - Product Information

Application	WB, IHC-P,E
Primary Accession	P43405
Other Accession	Q64725 , Q00655 , P48025
Reactivity	Human, Mouse
Predicted	Pig, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	72066
Antigen Region	387-417

SYK Antibody (C-term) - Additional Information**Gene ID** 6850**Other Names**

Tyrosine-protein kinase SYK, Spleen tyrosine kinase, p72-Syk, SYK

Target/Specificity

This SYK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 387-417 amino acids from the C-terminal region of human SYK.

DilutionWB~~1:1000
IHC-P~~1:50~100**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

SYK Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

SYK Antibody (C-term) - Protein Information**Name** SYK

Function Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development (PubMed:[12387735](#), PubMed:[33782605](#)). Assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine- phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent. Direct downstream effectors phosphorylated by SYK include DEPTOR, VAV1, PLCG1, PI-3-kinase, LCP2 and BLNK (PubMed:[12456653](#), PubMed:[15388330](#), PubMed:[34634301](#), PubMed:[8657103](#)). Initially identified as essential in B-cell receptor (BCR) signaling, it is necessary for the maturation of B-cells most probably at the pro-B to pre-B transition (PubMed:[12456653](#)). Activated upon BCR engagement, it phosphorylates and activates BLNK an adapter linking the activated BCR to downstream signaling adapters and effectors. It also phosphorylates and activates PLCG1 and the PKC signaling pathway. It also phosphorylates BTK and regulates its activity in B-cell antigen receptor (BCR)-coupled signaling. In addition to its function downstream of BCR also plays a role in T-cell receptor signaling. Plays also a crucial role in the innate immune response to fungal, bacterial and viral pathogens. It is for instance activated by the membrane lectin CLEC7A. Upon stimulation by fungal proteins, CLEC7A together with SYK activates immune cells inducing the production of ROS. Also activates the inflammasome and NF- kappa-B-mediated transcription of chemokines and cytokines in presence of pathogens. Regulates neutrophil degranulation and phagocytosis through activation of the MAPK signaling cascade (By similarity). Required for the stimulation of neutrophil phagocytosis by IL15 (PubMed:[15123770](#)). Also mediates the activation of dendritic cells by cell necrosis stimuli. Also involved in mast cells activation. Involved in interleukin-3/IL3-mediated signaling pathway in basophils (By similarity). Also functions downstream of receptors mediating cell adhesion (PubMed:[12387735](#)). Relays for instance, integrin-mediated neutrophils and macrophages activation and P-selectin receptor/SELPG- mediated recruitment of leukocytes to inflammatory loci. Also plays a role in non-immune processes. It is for instance involved in vascular development where it may regulate blood and lymphatic vascular separation. It is also required for osteoclast development and function. Functions in the activation of platelets by collagen, mediating PLCG2 phosphorylation and activation. May be coupled to the collagen receptor by the ITAM domain-containing FCER1G. Also activated by the membrane lectin CLEC1B that is required for activation of platelets by PDPN/podoplanin. Involved in platelet adhesion being activated by ITGB3 engaged by fibrinogen. Together with CEACAM20, enhances production of the cytokine CXCL8/IL-8 via the NFKB pathway and may thus have a role in the intestinal immune response (By similarity).

Cellular Location

Cell membrane. Cytoplasm, cytosol

Tissue Location

Widely expressed in hematopoietic cells (at protein level) (PubMed:[8163536](#)). Expressed in neutrophils (at protein level) (PubMed:[15123770](#)). Within the B-cell compartment, expressed from pro- and pre-B cells to plasma cells (PubMed:[8163536](#))


SYK Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)

- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


SYK Antibody (C-term) - Images




Western blot analysis of SYK (arrow) using rabbit polyclonal SYK Antibody (K402) (Cat. #AP7720b). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the SYK gene.



The anti-SYK Pab (Cat. #AP7720b) is used in Western blot to detect SYK in THP-1 cell lysate (Lane 1) and mouse spleen tissue lysate (Lane 2).



Anti-SYK Antibody (K402) at 1:1000 dilution + Raji whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 72 kDa Blocking/Dilution buffer: 5% NFDm/TBST.



Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.

SYK Antibody (C-term) - Background

Protein kinases are enzymes that transfer a phosphate group from a phosphate donor, generally the γ phosphate of ATP, onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. With more than 500 gene products, the protein kinase family is one of the largest families of proteins in eukaryotes. The family has been classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. The STE group (homologs of yeast Sterile 7, 11, 20 kinases) consists of 50 kinases related to the mitogen-activated protein kinase (MAPK) cascade families (Ste7/MAP2K, Ste11/MAP3K, and Ste20/MAP4K). MAP kinase cascades, consisting of a MAPK and one or more upstream regulatory kinases (MAPKKs) have been best characterized in the yeast pheromone response pathway. Pheromones bind to Ste cell surface receptors and activate yeast MAPK pathway.

The tyrosine kinase (TK) group is mainly involved in the regulation of cell-cell interactions such as

differentiation, adhesion, motility and death. There are currently about 90 TK genes sequenced, 58 are of receptor protein TK (e.g. EGFR, EPH, FGFR, PDGFR, TRK, and VEGFR families), and 32 of cytosolic TK (e.g. ABL, FAK, JAK, and SRC families).

SYK Antibody (C-term) - References

- Wang, L., et al., *Cancer Res.* 63(15):4724-4730 (2003).
Takada, Y., et al., *J. Biol. Chem.* 278(26):24233-24241 (2003).
Krishnan, S., et al., *J. Immunol.* 170(8):4189-4195 (2003).
Toyama, T., et al., *Cancer Lett.* 189(1):97-102 (2003).
Jiang, K., et al., *Blood* 101(1):236-244 (2003).